Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Crude response rates at 1 year of treatment with a first TNF inhibitor after stratification for different BMI categories

From: Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis

   BMI category  
Outcome n = 531 Normal
n = 282
Overweight
n = 178
Obese
n = 71
p
ASAS40 494 44% 34% 29% 0.02
 ASAS40 TNFi other than INF 383 45% 34% 24% 0.008
 ASAS40 TNFi: INF 111 42% 36% 44% 0.83
ASAS partial remission 531 39% 24% 17% <0.001
BASDAI-50 488 48% 40% 33% 0.06
ASDAS improvement ≥1.1 423 59% 46% 37% 0.003
ASDAS <2.1 468 56% 41% 25% <0.001
ASDAS improvement ≥2 423 25% 25% 13% 0.14
ASDAS <1.3 468 29% 15% 10% <0.001
  1. Normal weight = BMI 18.5–25; overweight = BMI 25–30; obese = BMI >30
  2. ASAS Assessment in SpondyloArthritis International Society, ASAS40 40% improvement according to ASAS, ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI-50 50% improvement in Bath Ankylosing Spondylitis Disease Activity Index, BMI body mass index, INF infliximab, TNFi tumor necrosis factor inhibitor